For the second consecutive yr, the pharmaceutical trade noticed its popularity slip amongst affected person advocacy teams, largely as a consequence of ongoing considerations over pricing points, in line with a brand new survey.
Of greater than 2,500 teams queried, 56% reported the trade had an “wonderful” or “good” popularity because it goes in regards to the enterprise of creating and offering medicines. Though the findings recommend a transparent majority had been principally glad with drug corporations, this marked a second consecutive annual decline — albeit, a slight one — after a number of years by which the trade was seen extra positively.
The earlier survey discovered that 57% of the teams indicated the trade had an “wonderful” or “good” popularity. The back-to-back declines come after 60% of affected person teams believed the trade fared nicely because of the preliminary response of many corporations to rapidly develop salves for the Covid-19 pandemic. In 2021, for example, 59% of corporations scored extremely, in contrast with 41% in 2018.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
